Endo (NDOI) Pre-Tax Income : $3,581 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Endo Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Endo's pretax income for the three months ended in Dec. 2024 was $0 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $3,581 Mil. Endo's pretax margin was %.

During the past 3 years, Endo's highest Pretax Margin was 237.76%. The lowest was -124.55%. And the median was -121.73%.

Endo Pre-Tax Income Historical Data

The historical data trend for Endo's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo Pre-Tax Income Chart

Endo Annual Data

Trend

Dec22

Dec23

Dec24

Pre-Tax Income

-2,888.10

-2,391.92

Endo Quarterly Data
	Jun23	Sep23	Dec23	Apr24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial			-16.89	-2,412.27	6,248.99	-255.59	-

Competitive Comparison of Endo's Pre-Tax Income

For the Drug Manufacturers - Specialty & Generic subindustry, Endo's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endo's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Endo's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Endo's Pre-Tax Income falls into.

Endo Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Endo's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	0	+	0	+	0	+	0	+	0
	=	0

Endo's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	0	+	0	+	0	+	0	+	0
	=	0

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,581 Mil.

Endo (OTCPK:NDOI) Pre-Tax Income Explanation

Endo's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	0	/	0
	=	%

During the past 3 years, Endo's highest Pretax Margin was 237.76%. The lowest was -124.55%. And the median was -121.73%.

Endo Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Endo's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Endo Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo Inc (OTCPK:NDOI) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.endo.com

Endo Inc is a diversified pharmaceutical company. It has four reportable business segments: (1) Branded Pharmaceuticals, (2) Sterile Injectables, (3) Generic Pharmaceuticals and (4) International Pharmaceuticals. Branded Pharmaceuticals segment includes a variety of branded products in the therapeutic areas of urology, orthopedics, etc. Sterile Injectables segment consists of branded sterile injectable products such as ADRENALIN, VASOSTRICT and APLISOL, among others. Generic Pharmaceuticals segment includes a product portfolio including patches, solid oral extended-release products, etc. Key revenue is generated from International Pharmaceuticals segment includes a variety of specialty pharmaceutical products, including OTC products, sold outside the U.S.